Comparison of the Acute Erythropoietic Capacities of Erythropoietin and U-74389G Concerning Mean Corpuscular Hemoglobin Levels

Aim: This study compared the erythropoietic capacities of erythropoietin (Epo) and antioxidant drug U-74389G based on 2 preliminary studies. The provided results at mean corpuscular hemoglobin (MCH) levels augmentation were co-evaluated in a hypoxia reoxygenation protocol of an animal model.Materials and methods: MCH levels (MCHl) were evaluated at the 60th reoxygenation min (for groups A, C and E) and at the 120th reoxygenation min (for groups B, D and F) in 60 rats. Groups A and B received no drugs, rats from groups C and D were administered with Epo; whereas rats from groups E and F were administered with U-74389G. Results: The first preliminary study of Epo non significantly increased the MCHl by 0.31%+0.16% (p-value=0.4430). However, the second preliminary study of U-74389G significantly rised the MCHl by 1.37%+0.37% (p-value=0.0005). These 2 studies were co-evaluated since they came from the same experimental setting. The outcome of the co-evaluation was that U-74389G has 4.362893-fold erythropoietic potency than Epo (p-value=0.0000). Conclusions: The anti-oxidant capacities of U-74389G accelerate the acute erythropoietic properties; presenting 4.362893-fold erythropoietic rise than epo (p-value=0.0000).